EP0076320A1 - Verfahren und vorrichtung zur behandlung von blut oder dergleichen - Google Patents
Verfahren und vorrichtung zur behandlung von blut oder dergleichenInfo
- Publication number
- EP0076320A1 EP0076320A1 EP82901649A EP82901649A EP0076320A1 EP 0076320 A1 EP0076320 A1 EP 0076320A1 EP 82901649 A EP82901649 A EP 82901649A EP 82901649 A EP82901649 A EP 82901649A EP 0076320 A1 EP0076320 A1 EP 0076320A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- blood
- fraction
- filtrate
- filtration
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 97
- 239000008280 blood Substances 0.000 title claims abstract description 97
- 238000000034 method Methods 0.000 title claims abstract description 46
- 210000003734 kidney Anatomy 0.000 claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims description 67
- 238000001914 filtration Methods 0.000 claims description 65
- 239000012528 membrane Substances 0.000 claims description 65
- 230000003416 augmentation Effects 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 12
- 238000002615 hemofiltration Methods 0.000 claims description 10
- 231100000331 toxic Toxicity 0.000 claims description 10
- 230000002588 toxic effect Effects 0.000 claims description 10
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000001846 repelling effect Effects 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000000306 component Substances 0.000 claims 29
- 239000012503 blood component Substances 0.000 claims 7
- 230000003134 recirculating effect Effects 0.000 claims 6
- 241001634830 Geometridae Species 0.000 claims 1
- 241000282320 Panthera leo Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 54
- 239000012530 fluid Substances 0.000 description 16
- 239000003792 electrolyte Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000002699 waste material Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000001223 reverse osmosis Methods 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229920002529 medical grade silicone Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000010891 toxic waste Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 244000089486 Phragmites australis subsp australis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007485 conventional hemodialysis Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- BCRCJODOYXQDHW-UHFFFAOYSA-N perchloric acid;propane-1,2,3-triol Chemical compound OCl(=O)(=O)=O.OCC(O)CO BCRCJODOYXQDHW-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3431—Substitution fluid path upstream of the filter
- A61M1/3434—Substitution fluid path upstream of the filter with pre-dilution and post-dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3455—Substitution fluids
- A61M1/3458—Substitution fluids having electrolytes not present in the dialysate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3455—Substitution fluids
- A61M1/3468—Substitution fluids using treated filtrate as substitution fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3601—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit
- A61M1/3603—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit in the same direction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7563—General characteristics of the apparatus with filters with means preventing clogging of filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Definitions
- This invention relates generally to an improved method fo filtering biological fluids including blood and, more specifically, to a method for filtering the blood of the kidney patient in order to remove accumulated waste components.
- the best known methods for removing waste materials from blood comprise various forms of dialysis.
- a portion of the blood water and low to moderate molecular weight waste materials diffuse through the membrane into the dialyzing fluid which must be continuously supplied in order to avoid electrolyte and toxin build-up which would stop or reduce the transfer of such materials from the blood.
- units based on this principle are widely available and fairly reliable, they have several disadvantages.
- the system as a whole is relatively complex and cannot be made readily portable.
- trained operator is required. Treatment typically involves a visit to the hospital or the like on the order of three times a week to remove the accumulated toxic waste build-up, adjust electrolytes in the body and remove any excess water.
- Treatment typically involves a visit to the hospital or the like on the order of three times a week to remove the accumulated toxic waste build-up, adjust electro
- efficient ultrafiltration is achieved by spiral geometry filter means with the blood flow parallel to the axis of the spiral an filtrate removal along the spiral in order to provide efficient blood filtration.
- the ultrafiltration method includes the use of a spiral filter and recirculation through the filter of a major fraction of the blood leaving the filter.
- Figure 1 shows the rejection characteristics of exemplary filters for use in this application.
- Figure 2 shows schematically a portion of a filter syste for removal, as an example, of middle molecular weight materi from a feed fluid.
- Figure 3 depicts important components of human blo including waste materials as a function of their molecular weig or cell size.
- Figure 4 shows the filtrate rate versus pressur characteristics of a filter suitable for removal of low an middle molecular weight materials from the blood.
- Figure 5 shows the clearance or removal rate versus th molecular weight of dissolved species as a function of th quantity of rejected materials (e.g. very high molecular weight proteins and/or cells) present on the filter membrane surface.
- rejected materials e.g. very high molecular weight proteins and/or cells
- Figure 6 is a schematic representation of an ultrafiltratio system suitable for blood and the like.
- Figure 7 is a plan view of a filter configuration suitable for use with the present invention.
- FIG. 8 illustrates the effect of recirculation through the convective feed path of the filter on its efficiency as a function of the blood composition and operating variables.
- the major fractions A and B spanning low and moderate molecular weights, include the electrolytes and at least a major portion of the toxins removed by the normal kidney.
- a third and fourth major fractions, C and D, of the blood have larger molecular weights and include proteins and antibodies.
- Fractions A, B, C and D together constitute the plasma portion of blood.
- the D fraction comprise molecular weights which range from approximately 45,000 to in excess of one million. Primarily platelets, red cells and white cells (the formed elements) exist in blood above the D fraction range .
- ultraf iltration has the potential to permit selective removal of undesired constituents without disturbing the rejected major fractions (Fraction D and the formed elements). For example, removal of the water/electrolyte/ toxin reactions (A and B) by filtration of blood through a membrane having a pore size
- Figures 1 and 2 Because most present filters have distribution of pore sizes, rejection may not occur precisely at and above a given particle size or molecular weight, but rathe increases over a limited range of particle sizes or molecula weights. To the extent that this range can be made to coincide with low concentration regions of the blood constituent spectrum, separation of the major blood constituents is possible. An intermediate component may be removed by the method depicted i
- the feed fluid i passed essentially normal to the plane of the filter.
- batch filtratio is feasible as a semi-continuous process because the water ca continue to flow through the sand which builds up on the upstrea side of the filter and filtration continues with only moderat increases in pressure.
- Batch filtration is not suitable fo continuous use with whole blood because the larger constituents effectively clog the filter and engender large pressure increase for a given filtrate rate. Filtration of blood can be made mor efficient and continuous"by the use of a convective filter wher the feed fluid flows approximately parallel to the filte membrane and thus tends to carry off those constituents of th fluid which decrease the filtrate rate.
- the clogging referred to herein can be two types ? surfa clogging and membrane pore clogging. Surfaceclogging is cause
- OMPI • / j .. IPO -* by rejected materials which accumulate on the surface (feed flui side) of the filter membrane The amount and density of thi type can be controlled by the methods, devices, and procedures described or referenced in this disclosure.
- the second type o clogging refers to constituents of the blood or other body fluid becoming immeshed within the membrane ultrastructure. This is, in general, less affected by convective events within the feed channel although there is still a possible mino contribution from events within the feed channel.
- the basic membrane filtration characteristics would be altered in the latter case wherein a different straight line buffered saline limit could be encountered (e.g. the straight line of Figure 4 would be rotated clockwise).
- Figure 4 shows how surface clogging affects the efficiency of filtration through its influence on the filtrate rate versus
- FIG. 6 shows schematically a preferred embodiment of this invention in the form of a kidney machine suitable for long term therapy.
- Input blood is extracted, as an example, from the patient's artery or internal fistula/shunt and passes to the input port 30 of the apparatus.
- the blood then passes to inpu port 3 of the convective ultrafilter 1.
- a pressure differentia TMP, across the filter membrane 9 causes water and wast components to separate from the blood circuit chamber 4 and pass through the membrane to the filtrate plenum 6.
- a portion of the filtrate withdrawn from the filter 1 may be discarded as indicated by W to withdraw excess water from the patient.
- the remainder of the filtrate is passed through a processor 11
- ⁇ COT ⁇ TUT ⁇ SHEET e.g. cartridges, secondary filters, etc. which removes waste materials (end products of metabolism, toxins) and adjusts the electrolyte concentration.
- the output of the processor 11 consists of water, electrolytes and nutrients at a rate F which is a fraction f of the input blood flow rate FF.
- This purified stream is returned to the patient and/or to the filter 1 as described in more detail hereinafter. That portion of the input blood which is not withdrawn as filtrate passes through and out of the convective filter at output port 5 of the filter and is returned to the patient's vein by way of apparatus output port
- Filter 11 preferably comprises a series of filters/cartridges each especially adapted to remove or change one or more of the plasma components. Suitable filters/cartridges are known to those skilled in the art and will not be described in detail here. Small quantities of makeup electrolytes, (such as calcium and magnesium), nutrients (such as glucose and/or amino acids) or medications (such as sodium bicarbonate, vitamins, etc.) may be added to the filtrate stream F which preferably also passes through a final bacterial filter before being returned to the patient; these details are not specifically shown in Figure 6.
- makeup electrolytes such as calcium and magnesium
- nutrients such as glucose and/or amino acids
- medications such as sodium bicarbonate, vitamins, etc.
- the convective filter 1 In order to achieve and maintain efficient ultrafiltration through filter 1, the convective filter 1 must be especially configured and operated using one or more forms of augmentation
- the input blood FF passes through th length L of the filter between the membrane elements 90.
- Elements 200 schematically represent a blood screen which serves to separate the membrane elements 90 by an appropriate distance, to introduce some resistance to flow into the blood path (whereb uniform flow is obtained) and to induce secondary flows which help keep the membrane clean.
- the model shown contains the membrane cast on a backing 400 sufficiently porous to allow easy flow of the filtrate towards the permeate collecting tube (500).
- Figure 6 is desirably on the order of 0.7 m for average adult intermittent application.
- the height H of the blood flow path is desirably in the range 0.25 to 1 mm? too small a value introduces excessive resistance into the blood flow path while too large a value results in inefficient filtration conditions and an impractically large filter.
- any impediments in the convective path do not appreciably reduce the effective width of the channel (i.e. active membrane) below its nominal value W.
- W effective width of the channel
- the filter consists of multiple hollow fiber membranes in a parallel arrangement, each with a bore diameter H, rapid plugging of a substantial number of the fibers can occur due to feed fluid concentration and the effective area is unacceptably diminished.
- W should be at least large as L.
- FIG. 7B and 7C there is shown a cross- section of a spiral filter.
- the membrane 9 ( Figure 6) comprises an envelope with the backing 400 from two opposing membranes elements 90 in contact 99 and glued together at the outer edges 66.
- the envelope and the blood screen 200 are both wound around central hollow mandrel 500 which serves as a conduit for th filtrate stream F.
- the porous backing 400 from envelope 9 open only onto holes 300 leading to the hollow portion of the mandrel
- the filtrate stream passes from the filter unit 1 throug the axis of the mandrel 500. Similarly, the blood passes throug the filter perpendicular to the drawing. More details of the construction of a spiral filter may be found in the Westmoreland
- the substrate materials have been described by Chevron Corp. Corp. and possibly polymethylmethacralate or other adhesive strategies common in the field.
- the substrate materials have been described by Roman numeral Corp. and possibly polymethylmethacralate or other adhesive strategies common in the field.
- the substrate materials have been described by Roman numeral Corp. and possibly polymethylmethacralate or other adhesive strategies common in the field.
- the substrate materials have been described by Roman numeral Corp. and possibly polymethylmethacralate or other adhesive strategies common in the field.
- the first type is an asymmetric cellulose acetate somewhat similar to the reverse osmosis membranes developed for desalinization.
- the exact annealing conditions will change with different cellulose acetate formulations and still produce an acceptabl membrane.
- the second type of membrane that can be used in hemofiltration is a modification of the newer, thin film composite reverse osmosis technology.
- the thin film composite reverse osmosis technology is, typically, a backing similar to the on
- the second modificatio of the thin film composite reverse osmosis technology would allo a thinner casting of the polysulfone base with an even thinne top film than is used in reverse osmosis.
- the criteria i easy passage of electrolytes and end products of metabolism wit insignificant passage of the larger plasma proteins. All of th modifications outlined above are easily accomplished by technical personnel well versed in membrane technology.
- the blood sid spacer 200 In order to achieve efficient hemof iltration, the blood sid spacer 200 must have certain characteristics. Many thick commercial screens will not work due to their ineffectiveness in
- Vexar made by DuPont (polyethelene), with 12 strands to the inch an measuring a total thickness of approximately 25 mils. (0.025 inches).
- the preferred orientation is to have the mesh lines at an approximate angle of 45° to the flow direction as shown in
- a preferred casting material to enclose the spiral filter and direct the blood and filtrate streams is polycarbonate or an equivalent biocompatible material.
- the same material has been used for the filtrate collection tube onto which the rolled spiral assembly is wound.
- the wound assembly is sufficiently smaller than the inside diameter of the polycarbonate housing, to enable potting of the wound assembly into the polycarbonate shell using medical grade silicone adhesive.
- Dimensions applicable to hemofiltration are a membrane width of 10 inches with a wound assembly diameter of 2 and 2/3 inches. This yields an effective membrane area considered to be a minimum for adult human intermittent application of 0.7 meters squared.
- Other details of construction are similar to existing spiral wound technology in the reverse osmosis field, with the exceptions of having to use biocompatible materials and avoiding turbulence in the blood flow path.
- a filter in accordance with the foregoing description will still not result in efficient hemof i ltrat ion unless it i operated as now described. It has been found essential for maintenance of efficiency to recirculate a large fraction of the blood exiting the filter at port 5 by reintroducing it a input port 3 at recirculation rate R times the input blood flo rate FF. R must be substantially larger than 2 with a nominal
- FF 200 to 250 cc/min.; values on the order of 3-8 are require to assure high efficiency with the filter membranes and device used hitherto and described hereinbefore. While there is a present no comprehensive and exact theoretical basis for th relation of the value of R to the filter parameters and bloo composition, most factors are known and at least two factors ar believed substantial.
- R the use of large amounts o recirculation R enhances the compositional homogeneity of th blood along the length of its flow path through the channel 4.
- typical blood input flow rate range is 200-250 cc/minute with typical filtrate rate of 80 cc/minute. Without recirculation, then, the plasma portion of the blood would be depleted o approximately half of its water by the time it reached output port 5.
- the filter input flow rate is in the range 1000-1250 cc/minute so that withdrawal of 80-100 cc/minute of water results in a much lower percentage change in blood composition down the length L of the filter.
- the increased rate of flow through the filter with recirculation is in the range 1000-1250 cc/minute so that withdrawal of 80-100 cc/minute of water results in a much lower percentage change in blood composition down the length L of the filter.
- Figure 8 gives data illustrative of the effect of th recirculation ratio R on the efficiency of the filter
- This efficiency relationship is further dependent on HCT, PH, TMP, and fibrinogen levels for a given filter design, i.e. H, W, L and screen design.
- the limit value for the efficiency ranges above 80% and depends inter alia on th variables indicated as well as other factors listed on Figure 8.
- Another method is to have the membrane supported by an irregula plastic insert with the transmembrane pressure sufficient t deform the membrane over the perturbation typically moded into the plastic support.
- An example of irregular but controlle channel geometries would include tight coiling of the feed channel, having periodic or asymmetric surface waviness paralle to the flow, and folding of the flow channel again in a manne to induce flow diversion in the direction of flow.
- the membrane can be constructed to contain fixed repellant charges.
- a tubular blood channel can benefit by using ribbon to produce spiral flow (secondary flows) in addition to axial flow through the tube. Examples of externally applie forces can include, but are not restricted to, the applicati of surface charge (in the absence of significant membrane charge electrically induced with the insertion of electrodes in eithe
- Ultrasound may be implemented in several ways, including crystals directly exposed to the feed channel. This is the most electrically efficient way of transmitting ultrasound frequency. It is also the least efficient in promoting filtration efficiency while posing the possibility of "heat" damage to the blood.
- a less electrically efficient way of producing ultrasound is to have the transducer face placed parallel to the direction of the feed flow, either in or underneath the membrane structure. Although less electrically efficient, the augmentation of filtration by the membrane is most effective with this orientation. Ultrasound reacts with any and all acoustic interfaces, one such important interface being the membrane/fluid junction.
- SUBSTITUTE SHEET Ultrasound techniques include the use of a single frequency, frequency spectra, and combination of frequencies dependen upon the application. Examples of physical movement include
- washing machine agitation, continuous rotation with speci rotating seals or connectors, or linear vibration, all applied t the entire filtering module.
- Staging of devices includes the use of more than one device arranged in a parallel and/or sequential manner. This allows direct introduction of cleanse filtrate into the feed flow between each module. This dilute the feed flow, allowing more efficient filtration in each module but normally at the price of increased total surface area (mor modules) with concomitant improvement in total clearance o effective filtration.
- Staging may also be of the macrostage variety, in which selected reintroduction of filtrate can be achieved by desig along an otherwise continuous flow channel. Staging is als meant to imply any method of intermittently "mixing up" the fee stream to eliminate any component polarization within the fee stream. Another variation of staging also found to be effectiv is the alternating of active and inactive filtering areas.
- independent control of biochemical and biophysical conditions includes the p H in the feed channel
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25367881A | 1981-04-13 | 1981-04-13 | |
| US253678 | 1994-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0076320A1 true EP0076320A1 (de) | 1983-04-13 |
Family
ID=22961257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP82901649A Withdrawn EP0076320A1 (de) | 1981-04-13 | 1982-04-13 | Verfahren und vorrichtung zur behandlung von blut oder dergleichen |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0076320A1 (de) |
| GB (1) | GB2108400A (de) |
| WO (1) | WO1982003567A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888115A (en) * | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
| DE3587885T2 (de) * | 1984-03-21 | 1994-11-03 | Mclaughlin William F | Filtration einer flüssigen Suspension. |
| US4689302A (en) * | 1984-04-02 | 1987-08-25 | Amerace Corporation | Spiral designed reactor |
| JPH0649137B2 (ja) * | 1984-11-15 | 1994-06-29 | バクスター・インターナショナル・インコーポレーテッド | 濾過装置に於る濾液流量制御システム及びその方法 |
| EP0215849B1 (de) * | 1985-03-13 | 1993-03-17 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Sammlungssystem für blutplättchen |
| US4869812A (en) * | 1985-08-12 | 1989-09-26 | Baxter International Inc. | Disposable diagnostic plasma filter dispenser |
| US6863821B2 (en) | 2002-02-02 | 2005-03-08 | Baxter International Inc. | Shear-enhanced systems and methods for removing waste materials and liquid from the blood |
| US8961789B2 (en) | 2008-10-31 | 2015-02-24 | Baxter International Inc. | Systems and methods for performing hemodialysis |
| WO2021056091A1 (en) * | 2019-09-26 | 2021-04-01 | Gerald John Vowles | An apparatus and method for semi-permeable membrane based blood filtration |
| WO2022133574A1 (en) | 2020-12-21 | 2022-06-30 | Volutrol Inc. | Wearable hemofiltration artificial kidney |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3367504A (en) * | 1964-12-21 | 1968-02-06 | Gulf General Atomic Inc | Spirally wrapped reverse osmosis membrane cell |
| US3579441A (en) * | 1968-04-19 | 1971-05-18 | Hydronautics | Blood purification by dual filtration |
| US3483867A (en) * | 1968-06-13 | 1969-12-16 | Meyer Markovitz | Artificial glomerulus and a method for treating blood |
| US3705100A (en) * | 1970-08-25 | 1972-12-05 | Amicon Corp | Blood fractionating process and apparatus for carrying out same |
| US4125462A (en) * | 1977-08-30 | 1978-11-14 | Rohm And Haas Company | Coated membranes |
-
1982
- 1982-04-13 EP EP82901649A patent/EP0076320A1/de not_active Withdrawn
- 1982-04-13 WO PCT/US1982/000449 patent/WO1982003567A1/en not_active Ceased
- 1982-04-13 GB GB08235450A patent/GB2108400A/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8203567A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2108400A (en) | 1983-05-18 |
| WO1982003567A1 (en) | 1982-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5194157A (en) | Blood purifying equipment particularly for the treatment of patients suffering from renal insufficiency, and a method of producing a reinfusion liquid for haemodiafiltration (HDF) | |
| US4648974A (en) | Process for the selective extracorporeal separation of blood constituents | |
| US7267771B2 (en) | Apparatus for therapeutic apheresis | |
| EP2214751B1 (de) | Verfahren und vorrichtung zur differenzierung von substanzen | |
| EP0111620B1 (de) | Verfahren und Vorrichtung zur Behandlung von Gesamtblut | |
| Colton | Analysis of membrane processes for blood purification | |
| JP2921848B2 (ja) | 細胞状要素を含む液体の生物特定浄化のための統合装置 | |
| KR101047970B1 (ko) | 용질을 선택적으로 추출하는 혈액의 체외 처리 장치 및 방법 | |
| JP3011463B2 (ja) | 治療用血液精製装置および血液透析濾過(hdf)用輸液の製造方法 | |
| EP0232885B1 (de) | Verfahren und Vorrichtung zum Trennen von Flüssigkeitsgemischen aufgrund ihrer Molekulargewichte | |
| KR20030066704A (ko) | 혈액 투석여과/혈액 여과 카트리지 | |
| EP0076321A1 (de) | Verfahren und vorrichtung zur hochwirksamen ultrafiltration komplexer flüssigkeiten | |
| US4609461A (en) | Apparatus for purifying blood | |
| US4692411A (en) | Separation of specific biological cells by a biochemical filter | |
| EP0076320A1 (de) | Verfahren und vorrichtung zur behandlung von blut oder dergleichen | |
| EP0966980A3 (de) | Methode zum schnellen Entfernen von fettlöslichen Zielmolekülen aus einer Kolloidlösung und Waschlösung für eine solche Methode | |
| US5679231A (en) | Gel bed dialyzer | |
| US5498340A (en) | Processing of protein-containing body fluids | |
| EP0327005B1 (de) | Verfahren zur extrakorporalen Behandlung von Ascites-Flüssigkeit | |
| EP0081101B1 (de) | Vorrichtung zur Behandlung von Blut und Verfahren zur Bluttrennung zur Plasmagewinnung | |
| Lysaght | The history of hemofiltration | |
| JPS59150506A (ja) | 液体中の特定物質の濃度を調節する方法および装置 | |
| CA1206888A (en) | Method and apparatus for treating whole blood | |
| JPS62236553A (ja) | 膜型血液浄化器の前処理方法 | |
| Dörp et al. | Optimization of hemofilters for the development of implantable artificial kidneys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): FR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19830607 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PIZZICONI, VINCENT BEATO Inventor name: MARKOVITZ, MEYER Inventor name: DORSON, WILLIAM JOHN, JR. |